Nieves Martinez Lago MD PhD

Thank you Colleagues for a phenomenal #ESMO26 ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME. 📣 101.7M impressions of potential reach 💬 6.1K posts on X from 988 participants in 34 countries ⚡ 43.1 posts per hour across the meeting days 😊 45% positive sentiment, with only 6% negative Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO 🏆 Top influencers @DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista 🌎 Where the conversation came from North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities. 🔬 Top studies by impact 1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts 2️⃣ VOLGA (bladder): 3.7M reach, 141 posts 3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach 4️⃣ SAFFRON (NSCLC): 3.3M reach 5️⃣ INTerpath-001 (melanoma): 154 posts Pinging our Collaborators

OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Risvutatug Rezetecan (Ris-Rez) Versus Gemcitabine and Docetaxel (GD) in Heavily Pretreated Patients With Relapsed or Refractory (R/R) Osteosarcoma: Primary Results From the Phase 3 ARTEMIS-011 Study 🦴 Phase 3 (n=122, China): B7-H3-directed ADC risvutatug rezetecan vs gemcitabine + docetaxel in R/R osteosarcoma after ≥2 prior lines; 25% adolescents. Primary endpoint: PFS by BICR. ➡️ Median PFS 5.5 vs 1.4 mo; HR 0.33; p<0.0001 ➡️ OS immature; HR 0.51 ➡️ Grade ≥3 TEAEs 92.5% vs 83.3%; treatment-related SAEs 63.8% vs 28.6% ✅ Significant PFS improvement with a favorable OS trend and manageable safety, highlighting potential as a new treatment standard for R/R osteosarcoma. 🎙️ Lu Xie (4Sight Made from Abstracts publicly available at the ESMO website)